Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Garo Armen

Agenus Inc.

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Metric
Company Name	Agenus Inc.	Sierra Oncology
Symbol	AGEN
MSH ID	COM:AGENUSBIO	COM:SIERRAONCOLOGY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	GB
Stage
Employee Count	389
Website	agenusbio.com	sierraoncology.com
LinkedIn
Founders

Metric
Market Cap	321.29M
Enterprise Value
Monthly Web Traffic	1.43K
Web Traffic Growth	0.48
Valuation
Raised Capital

Metric
Revenue	156.31M
Revenue (LTM)
Revenue (NTM)
Gross Profit	139.62M
EBITDA	-146.52M
Operating Income	-160.10M
Net Income	-245.76M
EPS	-0.69
Diluted EPS	-0.69
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.62
Operating Profit Margin	-0.71
EBITDA Margin	-0.94
Net Profit Margin	-1.40
Return on Equity	2.26
Return on Assets	-0.76
Return on Capital Employed	-2.75

COM:AGENUSBIO

Agenus Inc.

Last Close

2.86

22/11 21:00

Market Cap

66.82M

Beta: -

Volume Today

1.08M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.80
P/B Ratio	-1.87
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.29
EV Multiple	2.30

Metric
Days Sales Outstanding	3.73
Days Payables Outstanding	64.39
Days Inventory Outstanding	0.00
Operating Cycle	60.33
Cash Conversion Cycle	-66.99
Asset Turnover	0.63

Metric
Operating Cash Flow	-224.20M
Free Cash Flow	-234.16M
Cash Flow to Debt	-0.51
Operating Cash Flow/Sales	-0.90
Free Cash Flow Yield	-0.99

Metric
Cash & Equivalents	76.11M
Accounts Receivable	-23.46M
Inventory
Goodwill	24.72M
Debt to Capitalization	3.38
Debt to Assets	0.27
Current Ratio	0.63
Quick Ratio	0.40

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.21
R&D to Revenue	0.25
SG&A to Revenue	0.82